- Home
- FICO vs OCEAW Comparison
FICO vs OCEAW Comparison
Compare FICO & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FICO
- OCEAW
- Stock Information
- Founded
- FICO 1956
- OCEAW N/A
- Country
- FICO United States
- OCEAW United States
- Employees
- FICO N/A
- OCEAW 7
- Industry
- FICO Business Services
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- FICO Consumer Discretionary
- OCEAW Health Care
- Exchange
- FICO Nasdaq
- OCEAW Nasdaq
- Market Cap
- FICO 46.1B
- OCEAW N/A
- IPO Year
- FICO 1987
- OCEAW 2021
- Fundamental
- Price
- FICO $1,933.38
- OCEAW $0.02
- Analyst Decision
- FICO Buy
- OCEAW
- Analyst Count
- FICO 12
- OCEAW 0
- Target Price
- FICO $2,173.58
- OCEAW N/A
- AVG Volume (30 Days)
- FICO 182.9K
- OCEAW N/A
- Earning Date
- FICO 04-29-2025
- OCEAW N/A
- Dividend Yield
- FICO N/A
- OCEAW N/A
- EPS Growth
- FICO 21.78
- OCEAW N/A
- EPS
- FICO 21.79
- OCEAW N/A
- Revenue
- FICO $1,775,435,000.00
- OCEAW N/A
- Revenue This Year
- FICO $17.79
- OCEAW N/A
- Revenue Next Year
- FICO $15.57
- OCEAW N/A
- P/E Ratio
- FICO $88.90
- OCEAW N/A
- Revenue Growth
- FICO 14.49
- OCEAW N/A
- 52 Week Low
- FICO $1,105.65
- OCEAW N/A
- 52 Week High
- FICO $2,402.52
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- FICO 56.80
- OCEAW N/A
- Support Level
- FICO $1,791.23
- OCEAW N/A
- Resistance Level
- FICO $1,971.12
- OCEAW N/A
- Average True Range (ATR)
- FICO 87.30
- OCEAW 0.00
- MACD
- FICO 9.28
- OCEAW 0.00
- Stochastic Oscillator
- FICO 90.22
- OCEAW 0.00
About FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.